Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHA:603811)

SHA:603811 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	828.03	810.87	712.31	669.61	653.25	693.45
Other Revenue	1.48	1.48	2.06	2.01	1.72	0.52
Revenue	829.51	812.35	714.37	671.63	654.97	693.96
Revenue Growth	4.89%	13.72%	6.36%	2.54%	-5.62%	-8.46%
Cost of Revenue	257.75	254.26	225.17	248.45	217.8	208.98
Gross Profit	571.76	558.09	489.2	423.17	437.17	484.99
Selling, General & Admin	347.99	326.72	308.66	246.92	269.61	280.27
Research & Development	43.26	44.44	47.08	47.14	44.3	39.72
Other Operating Expenses	16.86	14.28	12.34	7.46	7.77	10.7
Operating Expenses	407.61	385.07	365.77	302.46	321.83	331.21
Operating Income	164.15	173.02	123.43	120.71	115.34	153.78
Interest Expense	-0.34	-3.83	-11.09	-15.26	-9.13	-4.52
Interest & Investment Income	20.1	33.33	46.28	67.12	49.08	31.87
Currency Exchange Gain (Loss)	-0.35	-0.35	0.01	-0.17	3.45	5.36
Other Non Operating Income (Expenses)	0.03	0.22	-0.07	-0.31	-0.11	-0.99
EBT Excluding Unusual Items	183.59	202.39	158.56	172.1	158.62	185.49
Impairment of Goodwill	-	-	-	-	-2.42	-2.92
Gain (Loss) on Sale of Investments	-	-	-	-	-3.55	10.69
Gain (Loss) on Sale of Assets	22.47	21.06	69.17	-0	0.06	-0.45
Asset Writedown	-4.32	-4.77	-24	-7.47	-0.41	-0.5
Other Unusual Items	6.82	5.16	14.4	9.44	11.53	5.19
Pretax Income	208.56	223.84	218.13	174.06	163.84	197.5
Income Tax Expense	17.63	26.38	17.35	12.01	2.66	26.27
Earnings From Continuing Operations	190.93	197.47	200.79	162.05	161.18	171.23
Minority Interest in Earnings	-1.77	-2.35	-0.09	0.85	0.4	-0.43
Net Income	189.16	195.12	200.7	162.9	161.58	170.8
Net Income to Common	189.16	195.12	200.7	162.9	161.58	170.8
Net Income Growth	-16.43%	-2.78%	23.21%	0.81%	-5.39%	3.42%
Shares Outstanding (Basic)	457	448	461	456	462	459
Shares Outstanding (Diluted)	457	448	461	456	462	459
Shares Change	1.00%	-2.78%	0.98%	-1.19%	0.66%	0.59%
EPS (Basic)	0.41	0.44	0.44	0.36	0.35	0.37
EPS (Diluted)	0.41	0.44	0.44	0.36	0.35	0.37
EPS Growth	-17.26%	0%	22.01%	2.03%	-6.02%	2.82%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	178.74	234.99	145.83	123.93	-86.92	9.38
Free Cash Flow Per Share	0.39	0.53	0.32	0.27	-0.19	0.02
Dividend Per Share	0.214	0.214	0.179	0.143	0.128	0.128
Dividend Growth	19.99%	19.99%	24.98%	11.99%	0%	0%
Gross Margin	68.93%	68.70%	68.48%	63.01%	66.75%	69.89%
Operating Margin	19.79%	21.30%	17.28%	17.97%	17.61%	22.16%
Profit Margin	22.80%	24.02%	28.09%	24.25%	24.67%	24.61%
Free Cash Flow Margin	21.55%	28.93%	20.41%	18.45%	-13.27%	1.35%
EBITDA	257.66	267.22	218.56	198.04	176.89	208.45
EBITDA Margin	31.06%	32.90%	30.59%	29.49%	27.01%	30.04%
D&A For EBITDA	93.51	94.2	95.13	77.32	61.55	54.67
EBIT	164.15	173.02	123.43	120.71	115.34	153.78
EBIT Margin	19.79%	21.30%	17.28%	17.97%	17.61%	22.16%
Effective Tax Rate	8.45%	11.78%	7.95%	6.90%	1.62%	13.30%
Revenue as Reported	215.32	812.35	714.37	671.63	654.97	693.96
Advertising Expenses	-	4.88	3.85	1.81	0.89	1.41

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error